RT Journal Article SR Electronic T1 The Plasmodium falciparum Drugome And Its Polypharmacological Implications JF bioRxiv FD Cold Spring Harbor Laboratory SP 042481 DO 10.1101/042481 A1 Yinliang Zhang A1 Li Xie A1 Lei Xie A1 Philip E. Bourne YR 2016 UL http://biorxiv.org/content/early/2016/03/05/042481.abstract AB Malaria is a disease contracted by over 200 million people each year, mostly in developing countries. The primary causative agent, Plasmodium falciparum (P. falciparum) has shown increased resistance to existing drugs, hence new treatments are needed quickly. To this end we performed a high-throughput systems-level analysis, mapping existing FDA drugs with the potential for repurposing against targets from the P. falciparum structural proteome. The resulting P. falciparum drugome (P.falciparum-drugome) was used to prioritize potential new anti-malaria candidate targets and highlight some novel FDA approved drugs that have apparent anti-malaria effects for possible use as multi-target therapeutics.